Patent intelligence · US
US 7678922
Processes for the preparation of 1,2,4-oxadiazole benzoic acids
Processes for the preparation of 1,2,4-oxadiazole benzoic acids
Patent details — US 7678922
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 16, 2010
- Expiration
- Mar 11, 2030
- Applicant
- PTC THERAPEUTICS, INC.
- Claims
- 15
- CPC classes
- A61P, A61P43/00
Quick answer
US 7678922 (Processes for the preparation of 1,2,4-oxadiazole benzoic acids) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Mar 16, 2010. Expires Mar 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61P, A61P43/00
More from PTC THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398140
Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
granted -
US 12384789
Compounds for treating Huntington's disease
granted -
US 12384797
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
granted -
US 12281083
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
granted -
US 12139499
Heteroaryl compounds for treating Huntington's disease
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12023335
Method for treating pancreatic cancer
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted
Frequently asked questions
What is US patent 7678922?
US 7678922 (Processes for the preparation of 1,2,4-oxadiazole benzoic acids) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Mar 16, 2010. Expires Mar 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7678922?
PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.
When does US 7678922 expire?
Our index shows an expiration date of Mar 11, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.